226 related articles for article (PubMed ID: 18278855)
1. Exploring inhibitor binding at the S' subsites of cathepsin L.
Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
3. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex.
Tsuge H; Nishimura T; Tada Y; Asao T; Turk D; Turk V; Katunuma N
Biochem Biophys Res Commun; 1999 Dec; 266(2):411-6. PubMed ID: 10600517
[TBL] [Abstract][Full Text] [Related]
4. The crystal structure of human cathepsin L complexed with E-64.
Fujishima A; Imai Y; Nomura T; Fujisawa Y; Yamamoto Y; Sugawara T
FEBS Lett; 1997 Apr; 407(1):47-50. PubMed ID: 9141479
[TBL] [Abstract][Full Text] [Related]
5. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
[TBL] [Abstract][Full Text] [Related]
6. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
7. Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode.
Inagaki H; Tsuruoka H; Hornsby M; Lesley SA; Spraggon G; Ellman JA
J Med Chem; 2007 May; 50(11):2693-9. PubMed ID: 17469812
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
[TBL] [Abstract][Full Text] [Related]
9. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
Thompson SK; Smith WW; Zhao B; Halbert SM; Tomaszek TA; Tew DG; Levy MA; Janson CA; DAlessio KJ; McQueney MS; Kurdyla J; Jones CS; DesJarlais RL; Abdel-Meguid SS; Veber DF
J Med Chem; 1998 Oct; 41(21):3923-7. PubMed ID: 9767629
[TBL] [Abstract][Full Text] [Related]
11. Peptide ketobenzoxazole inhibitors bound to cathepsin K.
McGrath ME; Sprengeler PA; Hill CM; Martichonok V; Cheung H; Somoza JR; Palmer JT; Janc JW
Biochemistry; 2003 Dec; 42(51):15018-28. PubMed ID: 14690410
[TBL] [Abstract][Full Text] [Related]
12. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
13. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
14. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.
Altmann E; Cowan-Jacob SW; Missbach M
J Med Chem; 2004 Nov; 47(24):5833-6. PubMed ID: 15537340
[TBL] [Abstract][Full Text] [Related]
15. Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker.
Slon-Usakiewicz JJ; Purisima E; Tsuda Y; Sulea T; Pedyczak A; Féthière J; Cygler M; Konishi Y
Biochemistry; 1997 Nov; 36(44):13494-502. PubMed ID: 9354617
[TBL] [Abstract][Full Text] [Related]
16. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.
Matsumoto K; Mizoue K; Kitamura K; Tse WC; Huber CP; Ishida T
Biopolymers; 1999; 51(1):99-107. PubMed ID: 10380357
[TBL] [Abstract][Full Text] [Related]
18. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of human cathepsin V.
Somoza JR; Zhan H; Bowman KK; Yu L; Mortara KD; Palmer JT; Clark JM; McGrath ME
Biochemistry; 2000 Oct; 39(41):12543-51. PubMed ID: 11027133
[TBL] [Abstract][Full Text] [Related]
20. A combined crystallographic and molecular dynamics study of cathepsin L retrobinding inhibitors.
Shenoy RT; Chowdhury SF; Kumar S; Joseph L; Purisima EO; Sivaraman J
J Med Chem; 2009 Oct; 52(20):6335-46. PubMed ID: 19761244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
